Study: NCT01332513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR1)
Description: Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR1)
Description: Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR1)
Description: Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR1)
Description: Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR1)
Description: Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR1)
Description: Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR2)
Description: Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR2)
Description: Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR2)
Description: Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR2)
Description: Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR2)
Description: Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR2)
Description: Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR3)
Description: Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR3)
Description: Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR3)
Description: Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR3)
Description: Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR3)
Description: Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR3)
Description: Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR4)
Description: Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR4)
Description: Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR4)
Description: Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR4)
Description: Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR4)
Description: Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR4)
Description: Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR5)
Description: Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR5)
Description: Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR5)
Description: Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR5)
Description: Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR5)
Description: Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR5)
Description: Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (IR)
Description: Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (IR)
Description: Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (IR)
Description: Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (IR)
Description: Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (IR)
Description: Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (IR)
Description: Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.